ORIC Pharmaceuticals, Inc.

DB:4TZ Stock Report

Market Cap: €585.5m

ORIC Pharmaceuticals Management

Management criteria checks 3/4

ORIC Pharmaceuticals' CEO is Jacob Chacko, appointed in May 2018, has a tenure of 6.67 years. total yearly compensation is $3.15M, comprised of 18.9% salary and 81.1% bonuses, including company stock and options. directly owns 1.1% of the company’s shares, worth €6.46M. The average tenure of the management team and the board of directors is 5.5 years and 4.8 years respectively.

Key information

Jacob Chacko

Chief executive officer

US$3.2m

Total compensation

CEO salary percentage18.9%
CEO tenure6.7yrs
CEO ownership1.1%
Management average tenure5.5yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jacob Chacko's remuneration changed compared to ORIC Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$120m

Jun 30 2024n/an/a

-US$111m

Mar 31 2024n/an/a

-US$102m

Dec 31 2023US$3mUS$596k

-US$101m

Sep 30 2023n/an/a

-US$93m

Jun 30 2023n/an/a

-US$93m

Mar 31 2023n/an/a

-US$90m

Dec 31 2022US$4mUS$572k

-US$89m

Sep 30 2022n/an/a

-US$91m

Jun 30 2022n/an/a

-US$85m

Mar 31 2022n/an/a

-US$85m

Dec 31 2021US$7mUS$536k

-US$79m

Sep 30 2021n/an/a

-US$84m

Jun 30 2021n/an/a

-US$91m

Mar 31 2021n/an/a

-US$81m

Dec 31 2020US$6mUS$489k

-US$74m

Sep 30 2020n/an/a

-US$54m

Jun 30 2020n/an/a

-US$35m

Mar 31 2020n/an/a

-US$30m

Dec 31 2019US$672kUS$456k

-US$27m

Dec 31 2018US$2mUS$290k

-US$21m

Compensation vs Market: Jacob's total compensation ($USD3.15M) is above average for companies of similar size in the German market ($USD975.18K).

Compensation vs Earnings: Jacob's compensation has been consistent with company performance over the past year.

CEO

Jacob Chacko (45 yo)

6.7yrs

Tenure

US$3,153,083

Compensation

Dr. Jacob M. Chacko, M.D., MBA, has been Chief Executive Officer and Director of ORIC Pharmaceuticals, Inc. since May 2018 and has been its President since May 2019. Dr. Chacko joined the ORIC Pharmaceutic...

Leadership Team

NamePositionTenureCompensationOwnership
Richard Heyman
Co-Founder9.8yrsUS$186.87k0.32%
€ 1.9m
Jacob Chacko
President6.7yrsUS$3.15m1.1%
€ 6.5m
Dominic Piscitelli
Chief Financial Officer5.3yrsUS$1.45m0.15%
€ 885.8k
Pratik Multani
Chief Medical Officer6.3yrsUS$1.51m0.066%
€ 388.0k
Charles Sawyers
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Scott Lowe
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Lori Friedman
Chief Scientific Officer5.5yrsno datano data
Christian Kuhlen
General Counsel4.8yrsno datano data
Daniel Iazzetti
VP & Head of People2.3yrsno datano data
Edna Chow Maneval
Senior Vice President of Clinical Development5.8yrsno datano data
Matthew Panuwat
Chief Business Officer6.2yrsno datano data
Keith Lui
Senior VP of Commercial & Medical Affairsless than a yearno datano data

5.5yrs

Average Tenure

57yo

Average Age

Experienced Management: 4TZ's management team is seasoned and experienced (5.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Richard Heyman
Co-Founder9.8yrsUS$186.87k0.32%
€ 1.9m
Jacob Chacko
President6.7yrsUS$3.15m1.1%
€ 6.5m
Charles Sawyers
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Scott Lowe
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Laurence Lasky
Member of Scientific Advisory Boardno datano datano data
Angie You
Independent Director3.2yrsUS$140.37k0%
€ 0
Lori Kunkel
Independent Director4.6yrsUS$133.87k0.029%
€ 170.1k
Mardi Dier
Independent Director4.9yrsUS$147.87k0%
€ 0
Steven Hoerter
Independent Director3.4yrsUS$141.37k0%
€ 0

4.8yrs

Average Tenure

62.5yo

Average Age

Experienced Board: 4TZ's board of directors are considered experienced (4.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 01:54
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ORIC Pharmaceuticals, Inc. is covered by 13 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Prakhar AgrawalCantor Fitzgerald & Co.
Yigal NochomovitzCitigroup Inc